Title |
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
|
---|---|
Published in |
Medical Oncology, April 2009
|
DOI | 10.1007/s12032-009-9218-8 |
Pubmed ID | |
Authors |
Thomas Nelius, Tobias Klatte, Werner de Riese, Allan Haynes, Stephanie Filleur |
Abstract |
For patients with docetaxel-resistant hormone-refractory prostate cancer (HRPC) no standard chemotherapeutic treatment exists. In this study, we evaluate the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in this patient population. Patients with metastatic HRPC with disease progression under docetaxel-based chemotherapy were eligible. The primary endpoint was prostate-specific antigen (PSA) response. Secondary endpoints were survival and toxicity. Low-dose CP (50 mg/d) and dexamethasone (1 mg/d) were administered orally in a metronomic manner. Treatment was continued until disease progression or intolerable side effects occurred. Seventeen patients were enrolled in this study. The median follow-up was 12 weeks (range: 4-60). Median age was 68 years (range: 42-85). Median PSA at study entry was 134 ng/ml (range: 46.0-6554). Nine patients had a PSA response (median 44.4%), four patients >or=50% and five patients <50%. Eight patients had a PSA progression. Overall survival was 24 months. Five patients reported a decrease in bone pain after 4 weeks' treatment. No grade 3 and 4 toxicities were noted. In this study, low-dose metronomically administered CP demonstrated efficacy as a second-line treatment in patients with docetaxel-resistant HRPC. The treatment was well tolerated and almost without toxicity. Further advantages of low-dose CP were its convenient oral administration, dosing schedule, low cost, and low-toxicity profile. These attributes in combination with immunoregulatory and antiangiogenic potentials make CP also a prime candidate for combination with other treatment regimens. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 46 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 26% |
Student > Bachelor | 5 | 11% |
Other | 5 | 11% |
Student > Master | 4 | 9% |
Lecturer | 3 | 7% |
Other | 8 | 17% |
Unknown | 9 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 28% |
Agricultural and Biological Sciences | 5 | 11% |
Chemistry | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Computer Science | 1 | 2% |
Other | 8 | 17% |
Unknown | 16 | 35% |